David Dai
Stock Analyst at Bernstein
(2.22)
# 2,795
Out of 5,149 analysts
32
Total ratings
44.83%
Success rate
-0.15%
Average return
Main Sectors:
Stocks Rated by David Dai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASML ASML Holding | Maintains: Outperform | $1,528 → $1,642 | $1,367.75 | +20.05% | 2 | Jan 22, 2026 | |
| SONY Sony Group | Maintains: Outperform | $33 → $30 | $21.49 | +39.60% | 1 | Jan 14, 2026 | |
| CATX Perspective Therapeutics | Maintains: Buy | $18 → $7 | $5.34 | +31.09% | 2 | Nov 21, 2025 | |
| KURA Kura Oncology | Maintains: Buy | $14 → $16 | $8.57 | +86.70% | 3 | Nov 14, 2025 | |
| BNTX BioNTech SE | Maintains: Neutral | $115 → $117 | $102.42 | +14.24% | 1 | Nov 6, 2025 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $35 → $38 | $22.10 | +71.95% | 3 | Nov 4, 2025 | |
| NUVL Nuvalent | Maintains: Buy | $114 → $132 | $101.49 | +30.06% | 3 | Oct 31, 2025 | |
| TLX Telix Pharmaceuticals | Maintains: Buy | $23 → $20 | $6.93 | +188.60% | 1 | Sep 23, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Buy | $30 → $26 | $15.99 | +62.60% | 2 | Jul 10, 2025 | |
| SMMT Summit Therapeutics | Initiates: Buy | $30 | $15.35 | +95.44% | 1 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $17 → $2 | $3.90 | -48.72% | 2 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $24 | $15.95 | +50.47% | 2 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $24 | $32.75 | -26.72% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $69 | $13.60 | +407.35% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $34.62 | +44.43% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $59.46 | +0.91% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $448 | $6.95 | +6,350.68% | 1 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $76.81 | -47.92% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $1.90 | +2,010.82% | 1 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $2.62 | +1,812.05% | 1 | Nov 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $41 → $52 | $25.62 | +102.97% | 1 | Mar 17, 2020 |
ASML Holding
Jan 22, 2026
Maintains: Outperform
Price Target: $1,528 → $1,642
Current: $1,367.75
Upside: +20.05%
Sony Group
Jan 14, 2026
Maintains: Outperform
Price Target: $33 → $30
Current: $21.49
Upside: +39.60%
Perspective Therapeutics
Nov 21, 2025
Maintains: Buy
Price Target: $18 → $7
Current: $5.34
Upside: +31.09%
Kura Oncology
Nov 14, 2025
Maintains: Buy
Price Target: $14 → $16
Current: $8.57
Upside: +86.70%
BioNTech SE
Nov 6, 2025
Maintains: Neutral
Price Target: $115 → $117
Current: $102.42
Upside: +14.24%
Syndax Pharmaceuticals
Nov 4, 2025
Maintains: Buy
Price Target: $35 → $38
Current: $22.10
Upside: +71.95%
Nuvalent
Oct 31, 2025
Maintains: Buy
Price Target: $114 → $132
Current: $101.49
Upside: +30.06%
Telix Pharmaceuticals
Sep 23, 2025
Maintains: Buy
Price Target: $23 → $20
Current: $6.93
Upside: +188.60%
Nurix Therapeutics
Jul 10, 2025
Maintains: Buy
Price Target: $30 → $26
Current: $15.99
Upside: +62.60%
Summit Therapeutics
Jul 1, 2025
Initiates: Buy
Price Target: $30
Current: $15.35
Upside: +95.44%
May 16, 2025
Downgrades: Neutral
Price Target: $17 → $2
Current: $3.90
Upside: -48.72%
May 12, 2025
Maintains: Buy
Price Target: $30 → $24
Current: $15.95
Upside: +50.47%
Oct 24, 2024
Initiates: Sell
Price Target: $24
Current: $32.75
Upside: -26.72%
Oct 24, 2024
Initiates: Buy
Price Target: $69
Current: $13.60
Upside: +407.35%
Oct 24, 2024
Initiates: Buy
Price Target: $50
Current: $34.62
Upside: +44.43%
Oct 24, 2024
Initiates: Buy
Price Target: $60
Current: $59.46
Upside: +0.91%
Mar 31, 2022
Initiates: Outperform
Price Target: $448
Current: $6.95
Upside: +6,350.68%
Mar 16, 2022
Initiates: Outperform
Price Target: $40
Current: $76.81
Upside: -47.92%
Feb 4, 2022
Initiates: Outperform
Price Target: $40
Current: $1.90
Upside: +2,010.82%
Nov 18, 2021
Initiates: Outperform
Price Target: $50
Current: $2.62
Upside: +1,812.05%
Mar 17, 2020
Upgrades: Outperform
Price Target: $41 → $52
Current: $25.62
Upside: +102.97%